Genetics of acquired long QT syndrome

Journal of Clinical Investigation

Volumn 115, Issue 8, 2005, Pages 2025-2032

  Roden, Dan M ^a   Viswanathan, Prakash C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ARSENIC TRIOXIDE; DISOPYRAMIDE; DOFETILIDE; DROPERIDOL; ERYTHROMYCIN; HALOPERIDOL; IBUTILIDE; METHADONE; PROCAINAMIDE; QUINIDINE; SOTALOL; THIORIDAZINE;

DISEASE PREDISPOSITION; ELECTROCARDIOGRAM; GENETIC VARIABILITY; HEART BLOCK; HEART FAILURE; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RISK FACTOR; STRESS; TORSADE DES POINTES;

ANIMALS; ETHER-A-GO-GO POTASSIUM CHANNELS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LONG QT SYNDROME; POTASSIUM CHANNELS, VOLTAGE-GATED; RISK FACTORS; SEX FACTORS; TORSADES DE POINTES;

EID: 23644450590     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI25539     Document Type: Review

References (95)

1. Viskin, S., Justo, D., Halkin, A., and Zeltser, D. 2003. Long QT syndrome caused by noncardiac drugs. Prog. Cardiovasc. Dis. 45:415-427.
2. Roden, D.M. 2004. Drug-induced prolongation of the QT Interval. N. Engl. J. Med. 350:1013-1022.
3. Dessertenne, F. 1966. La tachycardie ventriculaire à deux foyers opposés variables. Arch. Mal. Coeur Vaiss. 59:263-272.
4. Halkin, A., et al. 2001. Pause-dependent torsade de pointes following acute myocardial infarction. A variant of the acquired long QT syndrome. J. Am. Coll. Cardiol. 38:1168-1174.
5. Schwartz, P.-J., and Wolf, S. 1978. QT interval prolongation as a predictor of sudden death in patients with myocardial infarction. Circulation. 56:1074-1077.
6. de Bruyne, M.C., et al. 1999. Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. Eur. Heart J. 20:278-284.
7. Tomaselli, G.F., et al. 1994. Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation. 90:2534-2539.
8. Spargias, K.S., et al. 1999. QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure. Eur. Heart J. 20:1158-1165.
9. Barr, C.J., Naas, A., Freeman, M., Lang, C.C., and Struthers, A.D. 1994. QT dispersion and sudden unexpected death in chronic heart failure. Lancet. 343:327-329.
10. Zeltser, D., et al. 2003. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore). 82:282-290.
11. Moss, A.J., and Kass, R.S. 2005. Long QT syndrome: from channels to cardiac arrhythmias. J. Clin. Invest. 115:2018-2024. doi:10.1172/JCI25537.
12. Sanguinetti, M.C., and Bennett, P.B. 2003. Antiarrhythmic drug target choices and screening. Circ. Res. 96:491-499.
13. Kr potassium channel. Cell. 81:299-307.
14. Curran, M.E., et al. 1995. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 80:795-803.
15. Petersen, C.I., et al. 2004. In vivo identification of ether-a-go-go related gene-interacting proteins in Caenorhabditis elegans that affect cardiac arrhythmias in humans. Proc. Natl. Acad. Sci. U. S. A. 101:11773-11778.
16. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 97:175-187.
17. Mitcheson, J.S., Chen, J., Lin, M., Culberson, C., and Sanguinetti, M.C. 2000. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 97:12329-12333.
18. Sanchez-Chapula, J.A., Ferrer, T., Navarro-Polanco, R.A., and Sanguinetti, M.C. 2003. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol. Pharmacol. 63:1051-1058.
19. Fernandez, D., Ghanta, A., Kauffman, G.W., and Sanguinetti., M.C. 2004. Physicochemical features of the HERG channel drug binding site. J. Biol. Chem. 279:10120-10127.
20. Brachmann, J., Scherlag., B.J., Rosenshtraukh, L.V., and Lazzara, R. 1983. Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation. 68:846-856.
21. Strauss, H.C., Bigger, J.T., and Hoffman, B.F. 1970. Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ. Res. 26:661-678.
22. Dangman, K.H., and Hoffman, B.F. 1981. In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide. J. Pharmacol. Exp. Ther. 217:851-862.
23. Roden, D.M., and Hoffman, B.F. 1985. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ. Res. 56:857-867.
24. +-induced early afterdepolarizations in Purkinje fibers. J. Cardiovasc. Electrophysiol. 5:933-944.
25. Nattel, S., and Quantz, M.A. 1933. Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. Cardiovasc. Res. 22:808-817.
26. Burashnikov, A., and Antzelevitch, C. 1998. Acceleration-induced action potential prolongation and early afterdepolarizations. J. Cardiovasc. Electrophysiol. 9:934-948.
27. Wu, Y., Roden, D.M., and Anderson, M.E. 1999. Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. Circ. Res. 84:906-912.
28. Kober, L., et al. 2000. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet. 356:2052-2058.
29. Torp-Pedersen, C., et al. 1999. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N. Engl. J. Med. 341:857-865.
30. Antzelevitch, C. 2001. Transmural dispersion of repolarization and the T wave. Cardiovasc. Res. 50:426-431.
31. Belardinelli, L., Antzelevitch, C., and Vos., M.A. 2003. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol. Sci. 24:619-625.
32. KS contributes to the longer action potential of the M cell. Circ. Res. 76:351-365.
33. Zygmunt, A.C., Eddlestone, G.T., Thomas, G.P., Nesterenko, V.V., and Antzelevitch, C. 2001. Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am. J. Pbysiol. Heart Circ. Physiol. 281:H689-H697.
34. Shimizu, W., and Antzelevitch, C. 2000. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome J. Am. Coll. Cardiol. 35:778-786.
35. Ks heterogeneity on action potential duration and its rate dependence: a simulation study. Circulation. 99:2466-2474.
36. Van, G.X., and Antzelevitch, C. 1998. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation. 98:1928-1936.
37. Akar, F.G., Yan, G.X., Antzelevitch, C., and Rosenbaum, D.S. 2002. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation. 105:1247-1253.
38. Extramiana, F., and Antzelevitch, C. 2004. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation. 110:3661-3666.
39. Yan, G.X., and Antzelevitch, C. 1999. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 100:1660-1666.
40. Akar, F.G., and Rosenbaum, D.S. 2003. Transmural electrophysiological heterogeneities underlying arrhythmogenesis in heart failure. Circ. Res. 93:638-645.
41. Antzelevitch, C. 2004. Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem? J. Electrocardiol. 37(Suppl.):15-24.
42. Malik, M., and Camm, A.J. 2001. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf. 24:323-351.
43. Carlsson, L., Almgren, O., and Duker, G. 1990. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J. Cardiovasc. Pharmacol. 16:276-285.
44. Carlsson, L., Abrahamsson, C., Andersson, B., Duker, G., and Schiller-Linhardt, G. 1993. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc. Res. 27:2186-2193.
45. Chezalviel-Guilbert, F., et al. 1995. Proarrhythmic effects of a quinidine analog in dogs with chronic A-V block. Fundam. Clin. Pharmacol. 9:240-247.
46. Volders, P.G., et al. 1998. Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circulation. 98:1136-1147.
47. Thomsen, M.B., et al. 2004. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation. 110:2453-2459.
48. Jackman, W.M., et al. 1988. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog. Cardiovasc. Dis. 31:115-172.
49. Kay, G.N., Plumb, V.J., Atciniegas, J.G., Henthorn, R.W., and Waldo, A.L. 1983. Torsades de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J. Am. Coll. Cardiol. 2:806-817.
50. Roden, D.M., Woosley, R.L., and Primm, R.K. 1986. Incidence and clinical features of the quinidine-associaced long QT syndrome: implications for patient care. Am. Heart J. 111:1088-1093.
51. Makkar, R.R., Fromm, B.S., Steinman, R.T., Meissner, M.D., and Lehmann, M.H. 1993. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 270:2590-2597.
52. Locati, E.H., Maison-Blanche, P., Dejode, P., Cauchemez, B., and Coumel, P. 1995. Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings. J. Am. Coll. Cardiol. 25:1564-1575.
53. Choy, A.M., et al. 1997. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 96:2149-2154.
54. Tzivoni, D., et al. 1988. Treatment of torsade de pointes with magnesium sulfate. Circulation. 77:392-397.
55. - current in cardiac cells. Circ. Res. 80:782-789.
56. Wang, S., Liu, S., Morales, M.J., Strauss, H.C., and Rasmusson, R.L. 1997. A quantitative analysis of the activation and in activation, kinetics of HERG expressed in Xenopus oocytes. J. Physiol. 502:45-60.
57. Numaguchi, H. Johnson, J.P., Jr., Petersen, C.I., and Balser, J.R. 2000. A sensitive mechanism for cation modulation of potassium current. Nat. Neurosci. 3:429-430.
58. Kr implications for torsades de pointes and reverse use-dependence. Circulation. 93:407-411.
59. o and C-type inactivation. FEBS Lett. 417:43-47.
60. Choy, A.M.J., Darbar, D., Dell'Orto, S., and Roden, D.M. 1999. Increased sensitivity to QT prolonging drug therapy immediately after cardioversion to sinus rhythm. J. Am. Coll. Cardiol. 34:396-401.
61. Roden, D.M. 1998. Taking the idio out of idiosyncratic: predicting torsades de pointes. Pacing Clin. Electrophysiol. 21:1029-1034.
62. Donger, C., et al. 1997. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation. 96:2778-2781.
63. Napolitano, C., et al. 2000. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J. Cardiovasc. Electrophysiol. 11:691-696.
64. Yang, P., et al. 2002. Allelic variants in long QT disease genes in patients with drug-associated torsades de pointes. Circulation. 105:1943-1948.
65. Paulussen, A.D., et al. 2004. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J. Mol. Med. 82:182-188.
66. Splawski, I., et al. 2002. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science. 297:1333-1336.
67. Chen, S., et al. 2002. SNP S1103Y in the cardiac sodium channel gene SCN5A is associated with cardiac arrhythmias and sudden death in a white family. J. Med. Genet. 39:913-915.
68. Ackerman, M.J., et al. 2003. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin. Proc. 78:1479-1487.
69. Pharmacogenetics of Arrhythmia Therapy study group. 2005. KCNE2 genomic screening. http://www.pharmgkb.org/views/index.jsp?objld=69386 963&objCls=VariantPosition&view=AlleleFrequen cyInSampleSets.
70. Wei, J., et al. 1999. KCNE1 polymorphism confers risk of drug-induced long QT syndrome by altering kinetic properties of IKs potassium channels [abstract]. Circulation. 100:1-495.
71. Sesti, F., et al. 2000. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc. Natl. Acad. Sci. U. S. A. 97:10613-10618.
72. Hirschhorn, J.N., Lohmueller, K., Byrne, E., and Hirschhorn, K. 2002. A comprehensive review of genetic association studies. Genet. Med. 4:45-61.
73. Ioannidis J.P., Ntzani, E.E., Trikalinos, T.A., and Contopoulos- Ioannidis, D.G. 2001. Replication validity of genetic association studies. Nat. Genet. 29:306-309.
74. Viswanathan, P., and Rudy, Y. 1999. Pause induced early afterdepofarizations in the long QT syndrome: a simulation study. Cardiovasc. Res. 42:530-542.
75. The International HapMap Consortium. 2003. The International HapMap Project. Nature. 426:789-796.
76. Pfeufer, A., et al. 2004. A common haplotype in the 5′ region of the SCN5A gene is strongly associated with ventricular conduction impairment [abstract]. Circulation. 110:111-2293.
77. The CAST Investigators. 1989. Increased mortality due to encainide or flecainide in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. 321:406-412.
78. Woosley, R.L., Chen, Y., Freiman, J.P., and Gillis, R.A. 1993. Mechanism of the cardiotoxic actions of tetfenadine. JAMA. 269:1532-1536.
79. Wysowski, D.K., and Bacsanyi, J. 1996. Cisapride and fatal arrhythmia. N. Engl. J. Med. 335:290-291.
80. Rampe, D., Roy, M.L., Dennis, A., and Brown, A.M. 1997. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 417:28-32.
81. Nattel, S., Ranger, S., Talajic, M., Lemery, R., and Roy, D. 1990. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am. J. Med. 89:235-238.
82. Ray, W.A., et al. 2004. Oral erythromycin and the risk of sudden death from cardiac causes. N. Engl. J. Med. 351:1089-1096.
83. Fenichel, R.R., et al. 2004. Drug-induced torsades de pointes and implications for drug development. J. Cardiovasc. Electrophysiol. 15:475-495.
84. Haverkamp, W., et al. 2000. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur. Heart J. 21:1216-1231.
85. Anderson, M.E., Al Khatib, S.M., Roden, D.M., and Califf, R.M. 2002. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am. Heart J. 144:769-781.
86. Lazzara, R. 1989. Amiodarone and torsades de pointes. Ann. Int. Med. 111:549-551.
87. Shimizu, W., et al. 1995. Effects of verapamil and ptoptanolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J. Am. Coll. Cardiol. 26:1299-1309.
88. Antzelevitch, C., et al. 2004. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 110:904-910.
89. Antzelevicch, C., et al. 2005. Brugada syndrome: report of the second consensus conference. Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 111:659-670.
90. Jouven, X., Desnos, M., Guerot, C., and Ducimetiere, P. 1999. Predicting sudden death in the population: the Paris Prospective Study I. Circulation. 99:1978-1983.
91. Friedlander., Y., et al. 1998. Family history as a risk factor for primary cardiac arrest. Circulation. 97:155-160.
92. Fox, C.S., et al. 2004. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA. 291:2851-2855.
93. Darbar, D., et al. 2003. Familial atrial fibrillation is a genetically heterogeneous disorder. J. Am. Coll. Cardiol. 41:2185-2192.
94. Luo, C.H., and Rudy, Y. 1991. A model of the ventricular cardiac action potential. Depolarization, repolarization, and their interaction. Circ. Res. 68:1501-1526.
95. Gima, K., and Rudy, Y. 2002. Ionic current basis of electrocardiographic waveforms: a model study. Circ. Res. 90:889-896.